|
WO2021079337A1
|
|
Pharmaceutical formulation of anti-her2 antibody and preparation thereof
|
|
WO2021064589A1
|
|
Intranasal pharmaceutical compositions of cyclobenzaprine
|
|
US2021093598A1
|
|
Storage stable aqueous parenteral solutions comprising diclofenac
|
|
WO2021059234A1
|
|
Stable aqueous parenteral solutions of nonsteroidal anti-inflammatory drugs (nsaids)
|
|
WO2021048809A1
|
|
Novel substituted sulfoximine derivatives
|
|
US2021079000A1
|
|
Process for preparation of grapiprant
|
|
WO2021005546A1
|
|
Antibodies to human programmed death receptor pd-1
|
|
WO2021001804A1
|
|
Angptl3 based vaccine for the treatment of liver disease
|
|
US2020376017A1
|
|
Amorphous ertugliflozin and process for its preparation
|
|
WO2020183379A1
|
|
Novel salts, crystalline forms and premix of hypolipidemic agent
|
|
WO2020165782A1
|
|
Treatment for polycystic ovarian syndrome (pcos)
|
|
WO2020148619A1
|
|
Novel substituted sulfonylurea derivatives
|
|
WO2020128815A1
|
|
Saroglitazar for the treatment of hepatocellular carcinoma
|
|
WO2020234636A1
|
|
Novel compounds for the treatment of mammalian infections
|
|
US2020179339A1
|
|
Pharmaceuticals compositions for treatment of atopic dermatitis
|
|
WO2020089743A1
|
|
Pharmaceutical composition of pegylated l-asparaginase
|
|
WO2020089742A1
|
|
Anti-rabies monoclonal antibodies and cocktail thereof
|
|
WO2020084503A1
|
|
A composition comprising antibody with reduced level of basic variants thereof
|
|
US2020024250A1
|
|
Process for preparation of apalutamide
|
|
US2020062744A1
|
|
Processes for the preparation of filgotinib
|
